Sei Investments Co. Sells 47,740 Shares of ACADIA Pharmaceuticals Inc. $ACAD

Sei Investments Co. trimmed its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 31.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,390 shares of the biopharmaceutical company’s stock after selling 47,740 shares during the quarter. Sei Investments Co.’s holdings in ACADIA Pharmaceuticals were worth $2,368,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ACAD. Farther Finance Advisors LLC grew its position in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 386 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $26,000. Transamerica Financial Advisors LLC raised its position in ACADIA Pharmaceuticals by 304.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the period. Federated Hermes Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 1,185 shares during the last quarter. Finally, Leonteq Securities AG bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $52,000. Institutional investors own 96.71% of the company’s stock.

Analysts Set New Price Targets

ACAD has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday. Bank of America restated a “buy” rating and issued a $14.50 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Oppenheimer lifted their price objective on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the stock a “market perform” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Finally, Wall Street Zen raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.44.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ:ACAD opened at $29.21 on Friday. The firm has a market capitalization of $5.03 billion, a PE ratio of 13.16, a price-to-earnings-growth ratio of 17.19 and a beta of 0.81. The business has a 50 day simple moving average of $24.39 and a two-hundred day simple moving average of $23.27. ACADIA Pharmaceuticals Inc. has a 1 year low of $19.69 and a 1 year high of $29.48.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm had revenue of $308.00 million for the quarter, compared to the consensus estimate of $296.55 million. During the same period in the prior year, the business posted $0.16 earnings per share. The company’s revenue for the quarter was up 16.4% on a year-over-year basis. Equities research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current fiscal year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 14,292 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $29.22, for a total transaction of $417,612.24. Following the completion of the sale, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,981,934.16. This trade represents a 17.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the sale, the insider directly owned 24,509 shares of the company’s stock, valued at $519,100.62. This represents a 18.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 42,100 shares of company stock valued at $1,134,287 in the last quarter. 26.20% of the stock is owned by insiders.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.